Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sarepta Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Sarepta Therapeutics, Inc.

SRPT

Sarepta Therapeutics, Inc.

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics is a biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases. Its core focus includes treatments for Duchenne muscular dystrophy, LGMDs, and other neuromuscular disorders. The company develops proprietary exon-skipping and gene therapy platforms, commercializes multiple approved products, and collaborates globally to advance innovative genetic medicines for underserved patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Sarepta Therapeutics, Inc.

1
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports Q1 2026 Revenue of $730.8M, Net Income of $331M

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports 16% Revenue Growth to $2.2 Billion for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports 15% Revenue Decline and $179.9 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports 68% Revenue Growth to $611.1 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports 80% Revenue Growth but $447.5 Million Net Loss in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports $1.788 Billion in Revenue for 2024, Significant Net Income Turnaround

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Sarepta Therapeutics, Inc. Sarepta Therapeutics Reports 41% Revenue Growth in Q3 2024, Net Income Turnaround

Via official filing (AI summary) | over 1 year ago | 0 comments